Comparative efficacy of first-line therapies for advanced-stage chronic lymphocytic leukemia: A multiple-treatment meta-analysis
Cancer Treatment Reviews, 06/21/2012
Terasawa T et al. – Based on combined direct and indirect data, no single treatment showed significantly better overall survival than any other, and credible intervals were wide. Among six newer treatments with longer progression–free survival compared with chlorambucil, fludarabine–rituximab–based chemoimmunotherapy had the largest PFS benefit.